(Q37815128)

23 August 2017

1 reference

title

Jekyll and Hyde: the role of the microenvironment on the progression of cancer (English)

1 reference

23 August 2017

1

0 references

author name string

J Louise Jones

series ordinal

2

1 reference

23 August 2017

publication date

29 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

223

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

162-176

1 reference

Inflammation and cancer: back to Virchow?

23 August 2017

cites work

1 reference

The distribution of secondary growths in cancer of the breast. 1889

21 January 2018

1 reference

21 January 2018

Fibroblasts in cancer

1 reference

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

21 January 2018

1 reference

Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis

21 January 2018

1 reference

TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia

21 January 2018

1 reference

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.

21 January 2018

1 reference

Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4

21 January 2018

1 reference

The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells

21 January 2018

1 reference

Wnt activity defines colon cancer stem cells and is regulated by the microenvironment

21 January 2018

1 reference

Stromal induction of breast cancer: inflammation and invasion

21 January 2018

1 reference

Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma

21 January 2018

1 reference

Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions

21 January 2018

1 reference

Macro-environment of breast carcinoma: frequent genetic alterations in the normal appearing skins of patients with breast cancer.

21 January 2018

1 reference

Breast-cancer stromal cells with TP53 mutations.

21 January 2018

1 reference

No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas

21 January 2018

1 reference

Altered methylation of versican proteoglycan gene in human colon carcinoma

21 January 2018

1 reference

Distinct epigenetic changes in the stromal cells of breast cancers

21 January 2018

1 reference

Phenotypic and genetic alterations in mammary stroma: implications for tumour progression

21 January 2018

1 reference

Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases

21 January 2018

1 reference

Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer.

21 January 2018

1 reference

Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion.

21 January 2018

1 reference

Germ line polymorphism in metastatic progression

21 January 2018

1 reference

Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation

21 January 2018

1 reference

Tenascin-C in development and disease: gene regulation and cell function

21 January 2018

1 reference

mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma

21 January 2018

1 reference

Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody

21 January 2018

1 reference

Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines

21 January 2018

1 reference

Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms

21 January 2018

1 reference

Neurite outgrowth promotion by the alternatively spliced region of tenascin-C is influenced by cell-type specific binding.

21 January 2018

1 reference

Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12.

21 January 2018

1 reference

New insights into form and function of fibronectin splice variants

21 January 2018

1 reference

The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1.

21 January 2018

1 reference

Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin

21 January 2018

1 reference

Fibronectin as target for tumor therapy

21 January 2018

1 reference

Tensional homeostasis and the malignant phenotype

21 January 2018

1 reference

Matrix elasticity directs stem cell lineage specification

21 January 2018

1 reference

Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell

21 January 2018

1 reference

Matrix crosslinking forces tumor progression by enhancing integrin signaling

21 January 2018

1 reference

Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence

21 January 2018

1 reference

New functions for the matrix metalloproteinases in cancer progression

21 January 2018

1 reference

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion

21 January 2018

1 reference

The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype

21 January 2018

1 reference

The human myoepithelial cell exerts antiproliferative effects on breast carcinoma cells characterized by p21WAF1/CIP1 induction, G2/M arrest, and apoptosis

21 January 2018

1 reference

Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells.

21 January 2018

1 reference

Molecular characterization of the tumor microenvironment in breast cancer

21 January 2018

1 reference

Mechanisms of normal and tumor-derived angiogenesis

21 January 2018

1 reference

Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck

21 January 2018

1 reference

Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix

21 January 2018

1 reference

Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX.

21 January 2018

1 reference

Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

21 January 2018

1 reference

Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.

21 January 2018

1 reference

HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia

21 January 2018

1 reference

Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability

21 January 2018

1 reference

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

Role of hypoxia in the hallmarks of human cancer

21 January 2018

1 reference

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

21 January 2018

1 reference

The angiogenic switch in carcinogenesis

21 January 2018

1 reference

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

Targeting vascular endothelial growth factor in renal cell carcinoma

21 January 2018

1 reference

RETRACTED: Lysyl oxidase is essential for hypoxia-induced metastasis

21 January 2018

1 reference

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

21 January 2018

1 reference

Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha

21 January 2018

1 reference

Somatic mutations of the lysyl oxidase gene on chromosome 5q23.1 in colorectal tumors

21 January 2018

1 reference

Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers.

21 January 2018

1 reference

Molecular Mechanisms of Tumor Invasion and Metastasis: An Integrated View

21 January 2018

1 reference

Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival

21 January 2018

1 reference

Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling.

21 January 2018

1 reference

Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism

21 January 2018

1 reference

Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation

21 January 2018

1 reference

21 January 2018

1 reference

Tumour immunity: effector response to tumour and role of the microenvironment

21 January 2018

1 reference

Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy

21 January 2018

1 reference

A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth

21 January 2018

1 reference

Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors

21 January 2018

1 reference

Osteopontin-positive infiltrating tumor-associated macrophages in bulky ampullary cancer predict survival

21 January 2018

1 reference

Distinct role of macrophages in different tumor microenvironments

21 January 2018

1 reference

Role of tumor-associated macrophages in tumor progression and invasion

21 January 2018

1 reference

Alternative activation of macrophages

21 January 2018

1 reference

Exploring the full spectrum of macrophage activation

21 January 2018

1 reference

Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast

21 January 2018

1 reference

Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues.

21 January 2018

1 reference

Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2.

21 January 2018

1 reference

Hypoxia inhibits macrophage migration

21 January 2018

1 reference

Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy

21 January 2018

1 reference

Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy

21 January 2018

1 reference

Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer.

21 January 2018

1 reference

Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density.

21 January 2018

1 reference

T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor

21 January 2018

1 reference

Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.

21 January 2018

1 reference

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

21 January 2018

1 reference

CD25+ CD4+ regulatory T-cells in cancer

21 January 2018

1 reference

Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.

21 January 2018

1 reference

Stromal gene expression predicts clinical outcome in breast cancer

21 January 2018

1 reference

A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival

21 January 2018

1 reference

APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling

21 January 2018

1 reference

21 January 2018

1 reference

Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells

21 January 2018

1 reference

beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium

21 January 2018

1 reference

Clinical translation of angiogenesis inhibitors

21 January 2018

1 reference

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo

21 January 2018

1 reference

Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist

21 January 2018

1 reference

21 January 2018

1 reference

Integrins in angiogenesis: multitalented molecules in a balancing act.

21 January 2018

1 reference

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

21 January 2018

1 reference

Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents.

21 January 2018

1 reference

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.

21 January 2018

1 reference

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

21 January 2018

1 reference

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

21 January 2018

1 reference

Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.

21 January 2018

1 reference

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

21 January 2018

1 reference

Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo

21 January 2018

1 reference

Selective targeted delivery of TNFalpha to tumor blood vessels.

21 January 2018

1 reference

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

21 January 2018

1 reference

A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.

21 January 2018

1 reference

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.

21 January 2018

1 reference

Mechanism of action of lenalidomide in hematological malignancies

21 January 2018

1 reference

"Re-educating" tumor-associated macrophages by targeting NF-kappaB.

21 January 2018

1 reference

KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment

21 January 2018

1 reference

Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo

21 January 2018

1 reference

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

21 January 2018

1 reference

A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma

21 January 2018

1 reference

Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer

21 January 2018

1 reference

Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial

21 January 2018

1 reference

A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis

21 January 2018

1 reference

Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin

21 January 2018

1 reference

A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo

21 January 2018

1 reference

Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin

21 January 2018

1 reference

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer

21 January 2018

1 reference

Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer

21 January 2018

1 reference

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer

21 January 2018

1 reference

Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen

21 January 2018

1 reference

A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells.

21 January 2018

1 reference

Novel angiogenic inhibitor DN-9693 that inhibits post-transcriptional induction of connective tissue growth factor (CTGF/CCN2) by vascular endothelial growth factor in human endothelial cells

21 January 2018

1 reference

Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis.

21 January 2018

1 reference

Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition

21 January 2018

1 reference

Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions

21 January 2018

1 reference

Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways

21 January 2018

1 reference

Bryostatin-5 blocks stromal cell-derived factor-1 induced chemotaxis via desensitization and down-regulation of cell surface CXCR4 receptors

21 January 2018

1 reference

Blockade of the Stromal Cell–Derived Factor-1/CXCR4 Axis AttenuatesIn vivoTumor Growth by Inhibiting Angiogenesis in a Vascular Endothelial Growth Factor–Independent Manner

21 January 2018

1 reference

Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake

21 January 2018

1 reference

Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer

21 January 2018

1 reference

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

21 January 2018

1 reference

A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial

21 January 2018

1 reference

Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial

21 January 2018

1 reference

Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases

21 January 2018

1 reference

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

21 January 2018

1 reference

Breast-Cancer Stromal Cells withTP53Mutations and Nodal Metastases

21 January 2018

1 reference

Secretion of epidermal growth factor by macrophages associated with breast carcinoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PATH.2803

1 reference

23 August 2017

1 reference